Who can prescribe Strattera? NP vs MD

If you’re navigating ADHD treatment options, you’ve probably wondered: Can I actually get my medication through a video visit? The short answer is yes—especially for non-stimulant ADHD medications like Strattera (atomoxetine). But the longer answer involves understanding federal regulations, state-specific rules, and what legitimate telehealth care really looks like.

Let’s break down everything you need to know about accessing ADHD non-stimulant medications through telehealth in 2025.

Understanding Non-Stimulant ADHD Medications

Before we dive into telehealth regulations, it’s important to understand what makes non-stimulant ADHD medications different from their stimulant counterparts.

Strattera (atomoxetine) is the most commonly prescribed non-stimulant ADHD medication. Unlike Adderall or Ritalin, Strattera is not classified as a controlled substance by the DEA. This distinction is crucial because it means Strattera isn’t subject to the same federal prescribing restrictions that apply to stimulant medications.

Non-stimulant medications work differently in your brain. While stimulants increase dopamine and norepinephrine quickly (which is why they work within hours), Strattera gradually increases norepinephrine levels over several weeks. This makes it particularly suitable for people who:

• Have a history of substance use concerns
• Experience significant side effects from stimulants
• Have co-existing anxiety disorders
• Need consistent, all-day symptom coverage without the ‘wearing off’ effect

Because Strattera carries no risk of dependency or abuse, it offers more flexibility in how it can be prescribed—including via telehealth.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Rules: What’s Legal Right Now

The landscape of telehealth prescribing changed dramatically during the COVID-19 pandemic, and those changes are still in effect as we approach 2026.

The DEA’s Current Stance

The Drug Enforcement Administration extended telehealth prescribing flexibilities for controlled substances (like stimulant ADHD medications) through December 31, 2025. This ‘Third Temporary Extension’ allows healthcare providers to prescribe Schedule II-V controlled substances via telehealth without a prior in-person medical examination.

But here’s the key point for non-stimulant medications: Because Strattera isn’t a controlled substance, it was never restricted by federal telehealth rules in the first place. The Ryan Haight Act—which normally requires an in-person exam before prescribing controlled substances online—doesn’t apply to non-controlled medications like Strattera.

This means that from a federal standpoint, licensed providers have been able to prescribe Strattera via telehealth long before the pandemic, and they can continue to do so regardless of what happens with the DEA’s temporary extensions.

What Happens After December 2025?

While the DEA is expected to issue a fourth extension for 2026 (currently under review), this primarily affects stimulant medications. For patients seeking non-stimulant ADHD treatment, federal regulations aren’t the limiting factor—state laws are what matter most.

State-by-State Telehealth Rules for ADHD Treatment

While federal law gives a green light for non-stimulant telehealth prescribing, individual states have their own requirements. Here’s what you need to know about key states:

States with Minimal Restrictions

California, Illinois, and Pennsylvania have embraced telehealth with few additional requirements. In these states, a comprehensive video evaluation can establish a provider-patient relationship sufficient for prescribing ADHD medications, including non-stimulants. Providers must be licensed in the state and follow standard medical care protocols, but no mandatory in-person visits are required.

States with Specific Telehealth Requirements

Florida allows telehealth for ADHD treatment but has nuanced rules. The state generally prohibits telehealth prescribing of Schedule II stimulants—except when treating psychiatric conditions like ADHD. For Strattera, there are no special restrictions beyond requiring providers to use audio-visual technology (phone-only visits don’t count).

Texas is generally telehealth-friendly for mental health care. The state allows providers to prescribe ADHD medications via telehealth, though nurse practitioners face limitations on Schedule II stimulant prescribing in outpatient settings. For non-stimulants like Strattera, licensed NPs can prescribe under their collaborative practice agreements without issue.

States with Stricter Oversight

New York implemented stringent rules in 2025, requiring an initial in-person evaluation before prescribing any controlled substance via telemedicine. However, this requirement doesn’t affect Strattera prescriptions since it’s not a controlled medication. New York patients can still access non-stimulant ADHD treatment entirely through telehealth.

Alabama requires periodic in-person visits (within 12 months) for ongoing telehealth treatment in most cases. However, mental health services are specifically exempted from this rule. Since ADHD is a psychiatric condition, many Alabama providers can offer telehealth-only care for ADHD management, including Strattera prescriptions.

New Hampshire recently modernized its approach. As of August 2025, the state removed its prior in-person requirement and now only mandates an annual follow-up evaluation (which can be conducted via telehealth) for controlled medication prescribing. For non-controlled medications, there are no special visit requirements.

Who Can Prescribe ADHD Medications via Telehealth?

Not all healthcare providers have the same prescribing authority, and this varies significantly by state.

Physicians (MD/DO)

Licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth in all 50 states, provided they’re licensed in the state where the patient is located and follow applicable DEA regulations.

Nurse Practitioners and Physician Assistants

For non-stimulant medications like Strattera, nurse practitioners and physician assistants can prescribe in every state—though the level of supervision required varies:

• Independent practice states (like California, New York, Illinois, and New Hampshire) allow experienced NPs to prescribe without physician oversight after meeting certain requirements.

• Collaborative practice states (like Florida, Pennsylvania, and Texas) require NPs and PAs to work under physician supervision or with a collaborative agreement.

• Restricted states have additional limitations. For example, Georgia doesn’t allow NPs to prescribe Schedule II medications at all, and Texas limits NP/PA Schedule II prescribing to hospital or hospice settings. However, these restrictions don’t affect non-stimulant prescribing—NPs and PAs in these states can still prescribe Strattera under appropriate supervision.

When using a telehealth platform like Klarity Health, you’ll be matched with a provider who’s properly licensed and credentialed in your state, whether that’s a psychiatrist, psychiatric nurse practitioner, or physician assistant working within their scope of practice.

What to Expect During a Telehealth ADHD Evaluation

Legitimate telehealth ADHD care isn’t about quick prescriptions—it’s about thorough, evidence-based evaluation and treatment.

The Initial Assessment

Your first telehealth appointment will involve a comprehensive evaluation, typically lasting 45-60 minutes. Your provider will:

• Review your symptom history, focusing on when symptoms began and how they affect different areas of your life (work, school, relationships, daily functioning)
• Use standardized ADHD rating scales and DSM-5 diagnostic criteria
• Discuss your medical history, including any cardiovascular issues, mental health conditions, or substance use history
• Review any previous ADHD diagnoses or treatments
• Assess for conditions that can mimic or co-exist with ADHD, such as anxiety, depression, or sleep disorders

You may be asked to provide additional documentation, such as old report cards, performance reviews, or input from family members who can confirm your symptoms across different settings.

The Treatment Discussion

If your provider confirms an ADHD diagnosis, they’ll discuss treatment options. This conversation should include:

• The differences between stimulant and non-stimulant medications
• Why Strattera or another non-stimulant might be recommended for your situation
• Expected timeline for symptom improvement (typically 4-6 weeks for full benefits with Strattera)
• Potential side effects and how to manage them
• The importance of combining medication with behavioral strategies or therapy

At Klarity Health, providers take time to explain your options and answer questions. They’ll also discuss pricing transparently—whether you’re using insurance or paying out-of-pocket—so there are no surprises when you get your prescription filled.

Ongoing Monitoring

ADHD treatment isn’t a one-time prescription. You’ll have follow-up appointments to:

• Track symptom improvement
• Monitor for side effects (Strattera can affect blood pressure, heart rate, and mood—especially in the first few weeks)
• Adjust dosage if needed
• Address any new concerns or life changes affecting your ADHD

Most providers schedule a follow-up within 2-4 weeks of starting medication, then every 1-3 months once you’re stabilized.

Common Questions About Telehealth ADHD Treatment

Will My Pharmacy Accept a Telehealth Prescription?

Yes. Electronic prescriptions from licensed telehealth providers are processed the same way as in-person prescriptions. Most pharmacies won’t even know your prescription came from a telehealth visit—they just see an e-prescription from a licensed provider with a valid DEA number.

Strattera prescriptions face virtually no scrutiny since the medication isn’t controlled. You can typically receive 90-day supplies with multiple refills, making ongoing treatment more convenient.

Do I Need to Check a Prescription Monitoring Database?

Prescription Monitoring Programs (PMPs or PDMPs) track controlled substance prescriptions to prevent abuse and doctor shopping. Since Strattera isn’t a controlled substance, it’s not tracked in these databases, and providers aren’t legally required to check them before prescribing.

However, responsible providers often review your medication history anyway to:

• Identify potential drug interactions
• Understand your previous ADHD treatments
• Ensure comprehensive care coordination

Can I Switch from Stimulants to Non-Stimulants via Telehealth?

Absolutely. Many people discover that stimulants aren’t the right fit—whether due to side effects, concerns about controlled substance use, or simply inadequate symptom control. Your telehealth provider can safely transition you to Strattera or discuss other non-stimulant options like Qelbree (viloxazine) or Intuniv (guanfacine).

The transition process typically involves gradually reducing your stimulant medication while starting the non-stimulant, with close monitoring during the changeover period.

What If I Have Other Medical Conditions?

Certain medical conditions require extra caution when prescribing ADHD medications. Your telehealth provider will screen for contraindications such as:

• Narrow-angle glaucoma (absolute contraindication for Strattera)
• Severe cardiovascular disease (requires careful risk-benefit analysis)
• Liver problems (Strattera is metabolized by the liver and can rarely cause liver injury)
• History of MAOI antidepressant use (must wait 14 days after stopping an MAOI before starting Strattera)

If you have complex medical needs, your telehealth provider may coordinate with your primary care physician or refer you for in-person evaluation before prescribing.

Red Flags: What Legitimate Telehealth ADHD Care Should NOT Look Like

The ADHD telehealth industry has faced scrutiny in recent years, with some companies accused of over-prescribing stimulants without adequate evaluation. This has led to increased regulatory oversight and, unfortunately, damaged trust in telehealth services that are doing things right.

Warning Signs of Problematic Services

Be cautious of telehealth platforms that:

• Guarantee a prescription before you’ve even been evaluated
• Offer prescriptions after minimal assessment (5-10 minute consultations aren’t sufficient for ADHD diagnosis)
• Don’t require video visits (audio-only isn’t acceptable for initial ADHD evaluations in most states)
• Promise same-day medication delivery or don’t use licensed U.S. pharmacies
• Don’t verify your identity or medical history
• Never discuss non-medication treatment options

What Quality Telehealth Looks Like

Reputable services prioritize patient safety through:

• Comprehensive diagnostic evaluations using standardized criteria
• Licensed providers who are transparent about their credentials
• Clear communication about state-specific requirements and limitations
• Discussion of both medication and non-medication treatment approaches
• Regular follow-up appointments and symptom monitoring
• Coordination with your other healthcare providers when appropriate
• Transparent pricing and insurance verification

Klarity Health exemplifies this approach by ensuring every patient receives a thorough evaluation from a licensed provider, has access to both insurance and cash-pay options with clear pricing, and benefits from a network of available providers who can accommodate your schedule while maintaining clinical rigor.

The Cost of Telehealth ADHD Treatment

Understanding the financial aspect of telehealth ADHD care helps you make informed decisions.

Initial Evaluation Costs

Without insurance, initial psychiatric evaluations typically range from $200-$500. Follow-up appointments usually cost $100-$200. At Klarity Health, pricing is transparent upfront, and many patients find telehealth more affordable than traditional in-office psychiatry due to lower overhead costs.

Insurance Coverage

Most insurance plans now cover telehealth mental health services at the same rate as in-person visits, thanks to pandemic-era policies that have largely been made permanent. However, coverage varies by:

• Your specific insurance plan and network
• The provider’s insurance participation
• Your state’s telehealth parity laws

Klarity Health accepts many major insurance plans and can verify your coverage before your appointment, so you’ll know what to expect.

Medication Costs

Strattera is available as a generic (atomoxetine), which significantly reduces cost compared to brand-name versions. With insurance, generic atomoxetine typically costs $10-$50 per month. Without insurance, prices range from $30-$150 monthly, depending on your pharmacy and dosage.

Newer non-stimulants like Qelbree don’t yet have generic versions and can be more expensive, though manufacturer coupons are often available.

Looking Ahead: The Future of Telehealth ADHD Care

The regulatory landscape continues to evolve, and staying informed helps ensure uninterrupted access to care.

Expected Regulatory Changes

The DEA has proposed a ‘Special Registration’ framework that would create permanent pathways for telehealth prescribing of controlled substances with additional safeguards. While this primarily affects stimulant medications, it signals a broader acceptance of telehealth as a legitimate care delivery model.

For non-stimulant medications like Strattera, the outlook is stable. There’s no indication that access to non-controlled ADHD medications via telehealth will become more restrictive.

State-Level Trends

More states are moving toward:

• Permanent telehealth expansions (rather than temporary pandemic rules)
• Licensure compacts that allow providers to more easily practice across state lines
• Enhanced prescription monitoring to prevent abuse while maintaining access
• Telehealth parity laws requiring insurance to cover telehealth equivalently to in-person care

Best Practices for Patients

To ensure continuity of care as regulations evolve:

1. Maintain regular contact with your provider and attend scheduled follow-ups
2. Keep your provider informed if you plan to move to a different state
3. Use one pharmacy consistently to maintain a clear medication record
4. Be prepared for potential requirements like periodic in-person visits if your state’s laws change
5. Ask questions about backup plans if regulations shift

Is Telehealth ADHD Treatment Right for You?

Telehealth works best for patients who:

• Have relatively straightforward ADHD without severe complicating factors
• Can participate actively in video visits and provide detailed symptom history
• Are comfortable with technology and have reliable internet access
• Live in areas with limited access to in-person psychiatric care
• Prefer the convenience and often lower cost of virtual appointments

You might benefit from in-person evaluation if you:

• Have complex medical conditions requiring physical examination
• Need coordination of multiple specialists
• Have a history of severe psychiatric symptoms that haven’t been stabilized
• Are under age 12 (many telehealth platforms have age restrictions)
• Have concerns about substance use that require in-person support

Taking the Next Step

If you’re considering telehealth for ADHD treatment, particularly with non-stimulant medications, you have more options than ever before. The key is choosing a platform that prioritizes comprehensive evaluation, ongoing care, and patient safety.

Klarity Health connects you with licensed psychiatric providers who can conduct thorough ADHD assessments via secure video visits. With transparent pricing, acceptance of both insurance and self-pay options, and a network of available providers, Klarity makes it easier to access the care you need—without the long wait times typical of traditional psychiatry.

Whether you’re newly seeking an ADHD diagnosis, looking to try a non-stimulant medication, or hoping to transition from in-person to telehealth care, understanding your options and rights empowers you to make the best decision for your mental health.

Remember: legitimate telehealth ADHD care isn’t about taking shortcuts. It’s about leveraging technology to provide the same quality, evidence-based treatment you’d receive in person—often more conveniently and affordably. By choosing reputable providers and staying informed about the evolving regulatory landscape, you can access effective ADHD treatment that fits your life.

References

1. Fierce Healthcare. (2024, November). ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth.’ Retrieved from https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. McDermott Will & Emery. (2025). ‘DEA signals extension of telemedicine flexibilities for controlled substance prescribing for 2026.’ Retrieved from https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/

3. Sheppard Mullin Healthcare Law Blog. (2025, August). ‘Telehealth and in-person visits: Tracking federal and state updates to pandemic-era telehealth exceptions.’ Retrieved from https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

4. Medical News Today. (2025, January). ‘Is Strattera a controlled substance?’ Retrieved from https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

5. Center for Connected Health Policy. (2025). ’50 State Survey: Online Prescribing.’ Retrieved from https://www.cchpca.org/topic/online-prescribing/

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment